Research
Hormonal
SGLT-2 inhibitors produce modest weight loss (2.1-2.7 kg) in people with Type 2 Diabetes by inducing glucose-mediated osmotic diuresis, but are not yet approved specifically for obesity treatment.
SGLT-2 inhibitors (like Jardiance or Forxiga) are used for Type 2 Diabetes and cause modest weight loss (2-3 kg) by peeing out glucose. They are not approved for obesity treatment in non-diabetics, and the weight loss is less significant than with GLP-1 drugs.
GoodQualifiesHIGH confidence
One meta-analysis reported a mean weight loss of 2.1–2.7 kg associated with their use from phase III clinical trials in people with T2D... none are yet approved by the EMA or FDA specifically for the treatment of obesity
Why this rating
Based on meta-analyses of phase III trials in T2D patients.
Source
Drug Therapy in Obesity: A Review of Current and Emerging Treatments
David M. Williams et al. · Diabetes Therapy · 2020
DOI 10.1007/s13300-020-00816-y
narrative_reviewCited 196×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (specifically high-dose liraglutide 3.0 mg) produce clinically significant weight loss (5.9 kg/year) by enhancing satiety via hypothalamic stimulation and delaying gastric emptying.Good
- Multi-agonists (GLP-1/Glucagon, GLP-1/GIP, or GLP-1/GIP/Glucagon) show greater potential for weight loss than single-agonists by combining appetite suppression with increased energy expenditure.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →